TIVDAK tisotumab vedotin-tftm
Drug Class
Tissue Factor (TF) directed antibody-drug conjugate (ADC)靶向组织因子 (TF) 的抗体偶联药物 (ADC)
Mechanism
Binds to Tissue Factor on tumor cells and internalizes, releasing monomethyl auristatin E (MMAE), a microtubule disruptor, causing cell death.特异性结合肿瘤细胞表面的组织因子（TF）并内吞，在细胞内释放微管蛋白抑制剂单甲基奥瑞他汀E (MMAE)，导致有丝分裂受阻和细胞凋亡。
Approved Indication
FDA-approved for adult patients with recurrent or metastatic cervical cancer with disease progression on or after chemotherapy.FDA批准用于治疗在化疗期间或化疗后病情进展的复发性或转移性宫颈癌成人患者。
What This Means For Patients
TIVDAK is an antibody-drug conjugate targeting Tissue Factor for advanced cervical cancers. It is FDA-approved and clinically accessible inside Hainan Boao Lecheng.TIVDAK 是一种靶向组织因子（TF）的抗体偶联药物（ADC），用于晚期或转移性宫颈癌。其已获 FDA 批准，可在海南博鳌乐城先行区临床特许使用。
Regulatory Approvals
- FDA — approved (2024) — source
Pivotal Clinical Evidence
- innovaTV 301 — Vergote et al., N Engl J Med 2024 (NCT04697628) — DOI
Sources
This page provides regulatory and mechanism-of-action information for reference only. It is not medical advice, a treatment recommendation, or a guarantee of outcome. Availability is subject to individual clinical review.